News
SRNEQ
0.325
+3.17%
0.010
Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia
Yahoo · 6d ago
Affimed N.V. (AFMD) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 05/23 11:45
Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023
Yahoo · 05/22 13:00
Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/15 12:15
Sorrento Therapeutics, Inc.'s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers' Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts
PR Newswire · 05/14 19:00
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
NASDAQ · 05/09 12:15
Scilex Holding Company Announces Complete Enrollment Of A Phase 2 Study To Evaluate The Safety And Efficacy of SP-103 5.4%, Triple Strength Formulation Of ZTlido, For The Treatment Of Acute Low Back Pain
Benzinga · 05/04 13:03
Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
Yahoo · 04/28 13:00
Scilex Holding Co Announces That Its Majority Stockholder, Sorrento Therapeutics, Inc., Has Issued A Notice That Sorrento's Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Stock Distributed By Sorrento To Its Stockholders As A Dividend
Benzinga · 04/26 12:02
Scilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
Yahoo · 04/25 23:30
Sorrento Therapeutics, Inc.'s Bankruptcy Court Extends the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
PR Newswire · 04/25 23:01
Scilex Inks Distribution Agreement For Neuropathic Painkiller ZTlido In The Middle East And North Africa
Benzinga · 04/17 14:44
Scilex Holding Company Enters Into Master Distributor Agreement With CH Trading Group LLC And AD Ports Group For The Distribution Of ZTlido In The Middle East And North Africa Region
Benzinga · 04/17 13:13
Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders
Yahoo · 04/14 22:32
Bankrupt Drugmaker Sorrento’s Scilex Unit Explores Stock Sale
Yahoo · 04/13 16:25
Scilex ends rally after postponing annual shareholder meeting
Seeking Alpha · 04/06 15:22
Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders
Yahoo · 04/05 21:27
Why did Scilex stock rocket today? Court order on dividends
Seeking Alpha · 04/05 21:16
Sorrento announces court order requiring info on Scilex shares
Seeking Alpha · 04/04 19:19
Sorrento Therapeutics, Inc.'s Bankruptcy Court Requires Brokerages to Provide Information Related to Scilex Common Stock
PR Newswire · 04/04 17:49
More
Webull provides a variety of real-time SRNEQ stock news. You can receive the latest news about Sorrento Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SRNEQ
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.